Objective: Generalized convulsive seizures (GCS) are associated with high demands on the cardiovascular system, thereby facilitating cardiac complications.
| INTRODUCTION
People with epilepsy have an increased risk of sudden cardiac death and acute myocardial infarction, thereby contributing to the augmented risk of premature mortality. [1] [2] [3] [4] [5] The elevated cardiovascular morbidity and mortality may be, among others, due to the detrimental effects of antiseizure drugs on cardiac excitability and blood lipid profiles as a major risk factor of coronary artery disease as well as to epilepsy-related negative effects on the autonomic nervous system with enhanced sympathetic tone, thereby facilitating arterial hypertension and cardiac arrhythmias. Furthermore, periictal cardiac dysfunction is frequently observed in association with different seizure types and may be the cause of death in a significant proportion of people with epilepsy. 6, 7 Notably generalized convulsive seizures (GCS), including focal to bilateral tonic-clonic seizures and generalized-onset tonic-clonic seizures, put a strain on the cardiovascular system, which may promote cardiac complications such as cardiac arrhythmia, cardiomyopathy, and myocardial infarction. 6, 7 In line with this assumption, previous emergency room (ER) studies have reported troponin elevations after GCS in 6%-12% and acute myocardial infarction (AMI) in 2% of all cases referred because of GCS. 8 Patients with AMI in association with GCS were older and commonly had a history of coronary artery disease as compared to those without AMI. 8 In contrast to these observations in the ER, the sole prospective study that has investigated troponin levels in patients with video electroencephalography (video-EEG)-monitored seizures did not reveal detectable elevations of troponin in any patient, challenging the view that seizures alone induce cardiac injury. 9 Here, we hypothesized that the occurrence and extent of circulating biomarkers of cardiac injury depend on the features of GCS, and that the use of novel and maybe more sensitive biomarkers (including copeptin, suppression of tumorigenicity-2 [SST-2], growth differentiation factor 15 , soluble urokinase plasminogen activator receptor [suPAR] , and heart-type fatty acid binding protein [HFABP] ) increases the apparent proportion of GCS-related cardiac stress. [10] [11] [12] To address these issues, we investigated the alterations and time course of these biomarkers after video-EEG documented GCS.
| METHODS

| Patients
Adult patients age 18 years or older with refractory epilepsy who underwent video-EEG monitoring in the University Hospital Bonn Department of Epileptology (Bonn) for noninvasive presurgical evaluation or syndrome diagnosis were included in the study. Patients with known abnormalities in cardiac or renal function were excluded. The routine diagnostics comprised cerebral 3 Tesla magnetic resonance imaging (MRI), neuropsychological testing, and continuous video-EEG monitoring using noninvasive scalp-EEG recordings (Micromed system). A modified lead-I electrocardiography (ECG) with adhesive electrodes was recorded simultaneously with 2 chest electrodes; arterial oxygen saturation (SpO 2 ) was assessed with a fingertip pulse oximetry device.
| ECG analysis
R peaks were detected automatically and confirmed visually in 30-second epochs at different time points (1 minute before GCS, 1 minute postictally, and at the time of the blood sampling). The heart rate (HR) in beats per minute (bpm) was calculated from the detected RR intervals in milliseconds. HR variability (HRV) was expressed as the standard deviation (SD) of the normal to normal RR intervals (SDNN) in milliseconds. QT intervals were manually measured from the start of the QRS complex to the end of the T-wave as defined by the intersection with the isoelectric line. Three consecutive QT intervals were measured and corrected for the respective RR interval that preceded the QT waves. To minimize errors due to correction bias, we used 4 established formulas according to Bazett, Fridericia, Hodges, and Framingham.
| Blood samples
Blood samples were collected before occurrence of GCS and within 30 minutes as well as 2, 6, and 24 hours after a GCS. Two serum samples, 2 ethylenediaminetetraacetate (EDTA) samples, one lithium-heparin sample and one sodium fluoride sample (S-Monovette, by Sarstedt) were collected per time point and patient. One serum and EDTA sample were used immediately, and the others were centrifuged, frozen, and stored at −80°C until further analysis. cTNI and NT-proBNP were measured with Sandwich-
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| Seizures
Six GCS from 6 patients were generalized-onset tonic-clonic seizures; the remaining 30 GCS in 24 patients were focal to bilateral tonic-clonic seizures. The seizures lasted for~160 seconds (95% CI 86-233), and the tonic-clonic phase for~75 seconds (95% CI 61-89). Cyanosis occurred in 26 seizures (72.2%) 4 were without cyanosis (11.1%) and 6 could not be evaluated (16.7%). Patients were placed in the lateral recovery position and received oxygen via a nasal probe in the postictal period. SpO 2 sensors fell off the fingertips during most seizures, so that ictal SpO 2 measurements were inconsistent or not available in some patients. The mean of the available minimal SpO 2 data (in 28 GCS of 25 patients) was 82% (95% CI 79-86).
| ECG Data
ECG traces could be analyzed in all 36 seizures and were lacking in 2 patients, with 4 seizures only at the time of blood sampling. HR increased from~73 bpm (95% CI 67-78) preictally to~131 bpm (95% CI 122-139) (P < 0.001). HRV dropped from~47 msec (95% CI 67-years-old 36-59) to~32 msec (95% CI 17-47) 1 minute postictally and to 14 msec (95% CI 7-20) at the time of blood collection (P < 0.001). QTc showed significant alterations (P < 0.001), that is, QTc was lengthened when using Bazett and Hodges, whereas it appeared to be shortened when using Fridericia and Framingham correction formulas (see Figure 1 for details). No serious cardiac arrhythmias were observed during or after GCS. Sinus tachycardia occurred in 28 GCS, respiratory sinus arrhythmia in 5 GCS, and sinus tachycardia with supraventricular extrasystoles in one GCS. Supraventricular tachycardia with bundle branch block and tachycardia with intermittent idioventricular rhythm were observed in one GCS each, both converted into sinus tachycardia within 2 minutes after the seizure cessation. There were no significant changes of ST segment or other ECG alterations suggestive of myocardial ischemia in any case.
| Cardiac troponin I and high-sensitive troponin T
Complete measurements of cardiac troponin I up to 24 hours were available in 31 seizures from 30 patients. Three patients (10%) developed an increase of cTNI above the upper limit of normal (50 ng/L); one developed a rise of cTNI within the limits of normal. The cTNI peak was reached at 6 hours ( Figure 2A) . None of the patients had cardiac complaints, and results of subsequent 12-lead ECG and transthoracic echocardiography were without significant abnormalities. Complete measurements of hsTNT up to 24 hours were available in 23 seizures from 23 patients, and partial measurements without the baseline value were available in 30 patients. Six patients (~26%) showed a rise in hsTNT above the upper limit of normal (14 ng/L), one of whom displayed a maximum value exceeding 50 ng/L. The hsTNT values of the remaining 17 patients tended to increase slightly within normal limits (P < 0.001; Figure 2B ). Dopamine levels correlated with cTNI (r = 0.53; P = 0.001) and hsTNT (r = 0.58; P = 0.001).
(See Figure 2 and Table 2 for details.)
| Copeptin, NT-proBNP, and catecholamines
Complete copeptin measurements from baseline to 24 hours were available in 31 seizures from 30 patients. Copeptin showed a >30-fold increase (P < 0.001) after the GCS, quickly fell after 2 hours, and returned to baseline levels after 6 hours. About 86% (31/36) of the seizures led to copeptin levels that exceeded the upper limit of normal (28.7 pmol/L) and 94.4% of the seizures (34/36) reached levels above 10 pmol/L, a cutoff value proposed to screen for acute myocardial infarction ( Figure 2C , Table 2 ). Complete NT-proBNP measurements from baseline to 24 hours were available in 28 seizures of 28 patients with no changes over time (P = 0.28), except in 2 patients who had a peak at 6 hours with levels above 250 pg/mL. Catecholamine data were available in 34 seizures from 30 patients. Levels were significantly elevated postictally and returned to baseline values after 2 hours ( Figure 3 , Table 2 ).
| Novel markers: SST-2, HFABP, suPAR, and GDF-15
Full measurements from baseline to 24 hours were available in 27 seizures and patients for SST-2, HFABP, and GDF-15 and from 26 seizures and patients for suPAR. Figure 4 illustrates the time course of these markers. SST-2 showed a 1.2-fold (P < 0.001) increase after 6 hours and remained elevated at 24 hours. Most patients had HFABP levels below the measuring range. One individual with tuberous sclerosis complex without known cardiac affection had constantly elevated levels. Six other individuals developed mild elevations of HFABP; only 2 of them also had a concomitant increase in cTNI and hsTNT. Altogether, baseline HFABP doubled (P = 0.006) 2 hours after GCS and returned to baseline levels at 6 hours. GDF-15 increased 1.2-fold (P = 0.02) 6 hours after GCS. SuPAR levels remained stable throughout the investigated time with a trend (P = 0.082) toward slightly higher levels early after GCS, quickly returning toward baseline values within 2 hours. (See Table 2 for details.)
| Factors related to elevated troponin levels
To identify factors associated with altered cardiac stress markers, we compared the group with increased hsTNT above 14 ng/L and/or cTNI above 50 ng/L (n = 6) to those without (n = 24 , and minimally measured SpO 2 (75%, 95% CI 57-93% vs 84%, 95% CI 80-87%; P = 0.16) did not differ significantly between the groups. Furthermore, the blood levels of copeptin immediately after the GCS, HFABP after 2 hours, and SST-2 after 6 hours did not differ between the groups. There were no statistically significant differences regarding seizure-onset zone (temporal vs extratemporal or generalized-onset: 11 of 24 patients without increased hsTNT vs 4 of 6 patients with increased hsTNT; P = 0.65), the presence of cardiovascular risk factors (10 of 24 patients vs 4 of 6 patients; P = 0.378), or the occurrence of multiple vs single seizures during the study period (7 of 24 patients vs 2 of 6 patients; P = 1).
F I G U R E 1 Periictal ECG features. Point plots and summary bar graphs of heart rate (A), heart rate variability (B), and corrected QT intervals (C,D) NASS ET AL.
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| DISCUSSION
The major findings of the present study are that (a) GCS are associated with elevations in high-sensitive troponin T in a significant proportion of epilepsy patients without known cardiac disease, and that (b) these troponin elevations were correlated with postictal dopamine levels indicating an association with catecholaminergic overdrive. Furthermore, (c) copeptin was increased in most GCS in the early postictal phase by more than 30-fold on average.
Consequently, copeptin appears to be a highly sensitive marker of GCS but does not indicate clinically harmful troponin elevations after GCS.
| Biomarkers of cardiac injury
Troponin and BNP were previously studied in retrospective ER and intensive care unit (ICU) studies, 8, 13 but only one prospective study has investigated serial troponin levels in 11 patients with video-EEG-monitored seizures without elevations of troponin in any patient. 9 In the present study with 30 patients, mild cTNI elevations were found in 10% and mild elevations of the more sensitive hsTNT in 26% of the patients. In contrast to a previous report, significant changes of the ST segment or other ECG alterations suggestive of myocardial ischemia were not detected in any patient. 14 Furthermore, none of our patients had apparent cardiac symptoms, known coronary artery disease (CAD), or prominent cardiovascular risk factors. Although they were significantly older than those without troponin elevations, 3 of them were younger than 40 years. Because troponin elevations were mild and asymptomatic, ischemia is not the likely mechanism of cardiac stress. Takotsubo cardiomyopathy and neurogenic stress cardiomyopathy are not uncommon after cerebrovascular damage, are associated with very high catecholamine levels leading to contraction band necrosis, and present with elevated troponin levels, transient ventricular motion abnormalities, and ECG changes mimicking acute ischemia in the absence of CAD. [15] [16] [17] Because none of our patients displayed such signs, seizure-related troponin elevations may be a mild form of neurogenic stress cardiomyopathy. The very high-stress level in stroke or subarachnoid hemorrhage (SAH) lasts for hours or days, whereas it resolves within minutes to hours after a GCS. This may explain the milder phenotype after single GCS and the more common and distinct clinical course after status epilepticus. A factor that is clearly not present in stroke and SAH, where patients are typically immobilized, is the extreme muscular effort that occurs during GCS. Troponin elevations related to strenuous exercise may be an alternative explanation for our findings. However, exercise-induced troponin elevations are commonly found in extreme endurance exercises, 18 and not so much after single bouts of "all out" exercise, which would be more like GCS. 19 Release of catecholamines, known for decades in epilepsy, 20 is a key factor in both phenomena.
In fact, patients with troponin elevations had higher dopamine levels and lower HRV levels, a surrogate marker for sympathetic activity. Copeptin is released with arginine vasopressin, which promotes antidiuresis and vasoconstriction to elevate blood pressure. It is a negative prognostic stress marker in stroke, sepsis, and AMI . 8, 10 It helps to distinguish between patients with chest pain who need hospitalization and patients who are not immediately threatened. 10 Copeptin levels above a proposed cutoff value of 10 pmol/L were found in 94% of our patients and reached the 30-fold average baseline level within minutes after the GCS. Levels below 10 pmol/L are thought to rule out Significant P values for pair-wise comparisons are shown at the top of each graph. Bars represent means with 95% CIs. Dots present individual measurements. The dotted horizontal lines in A and C indicate the upper limit of the normal range; the lower dotted horizontal line in B also shows the upper limit of normal, whereas the upper dotted line represents the value above which infarction is deemed to be likely myocardial infarction in the setting of chest pain. 21 Because copeptin elevations affect most GCS patients, it does not help to distinguish GCS-related troponin elevations from troponin elevations due to life-threatening acute coronary syndrome. As copeptin levels are increased after almost every GCS, it is unlikely to be a helpful predictor for clinical outcome, as shown in a study on the clinical outcome in ER patients after a seizure. 22 Copeptin is released from the pituitary gland, probably due to overexcitation of hypothalamic neurons during the seizures. Alongside the catecholamines and direct activation of the autonomous nervous system activity, however, its effects on fluid homeostasis and blood vessels may contribute to postictal autonomic changes such as the altered baroreceptor response 23 and altered lung fluid flux. 24 High levels of SST-2, GDF-15, suPAR, and HFABP are associated with a number of unfavorable clinical outcomes, for example, the development of heart failure and length of hospital stay after AMI. 11 These novel cardiac markers showed subtle but significant increases yet did not reach levels reported in AMI. 11 GDF-15 was the only novel cardiac biomarker in our sample that was higher in the group with elevated troponin levels as compared to the patients without. SuPAR was the only novel cardiac biomarker without significant changes in the postictal period. Therefore, it might be a useful biomarker to distinguish between GCS-related cardiac stress and genuine cardiac pathology, since suPAR elevations were described in studies of acute cardiac ischemia and chronic heart failure. It is, however, important to note that suPAR is also elevated in several other chronic diseases and thus cannot be expected to be very specific. 11, 25 Future studies in this field should address direct comparisons between the different patient groups.
| Limitations
The sample size was too small to obtain a sufficient number of troponin elevations to apply advanced statistical methods such as logistic regression or comparisons with large cardiologic study populations. The underlying mechanism of troponin leaks was not studied with advanced cardiac imaging that would rule out subtle CAD or mild takotsubo cardiomyopathy. Seizure-related occurrence of cardiac arrhythmias was recently reported to be linked to periictal oxygen desaturation. 26 In our patient group, however, SpO 2 monitoring was unreliable and did not allow further subgroup analyses, which may have provided additional insight into the relationship between seizure-related hypoxemia and cardiac arrhythmias or release of circulating markers of cardiac injury. hours. An outlier with a level of 21 130 pg/mL was clipped at the axis limit. B, Heart-type fatty acid binding protein (HFABP) remained below the detection level in most patients; the average doubled at 2 hours. Pair-wise comparisons did not show significant HFABP changes between the time points. One individual with tuberous sclerosis had very elevated levels throughout the whole study, never falling below 7.8 ng/mL; the corresponding data points were clipped at the axis limit. C, Growth differentiation factor 15 (GDF-15) increased 1.2-fold at 6 hours. Soluble urokinase plasminogen activator receptor remained stable (D). All measurements are plotted (30 seizures in 29 patients) but only complete measurements (28 seizures in 28 patients) were used for repeated-measures Friedman tests. Significant P values for pair-wise comparisons are shown at the top of each graph. Bars represent means with 95% CIs. Dots present individual measurements microinjuries may become the structural origin of future cardiac arrhythmias and even sudden cardiac death. This assumption is strengthened by the fact that subtle fibrotic lesions in the heart were described in people with epilepsy and in cases of sudden unexpected death in epilepsy (SUDEP). 7 Thus, single GCS are unlikely to lead to acute deleterious cardiac injuries in a significant proportion of epilepsy patients without cardiac disease but may promote the development of potentially detrimental structural changes that facilitate future cardiac arrhythmias. Another outcome of our study is that copeptin appears to be a robust blood marker of GCS. However, elevations of copeptin in the setting of syncope have been described recently, challenging its discriminative value for GCS from episodes of other origins. 27 In this context, it is important to stress that copeptin can be significantly elevated in association with other diseases such as ischemic stroke, subarachnoid hemorrhage, septic shock, and other medical conditions with impaired levels of consciousness or focal neurologic deficits that could possibly be confused with postictal states or postictal Todd phenomenon. 8 Future studies are required to elucidate the sensitivity and specificity of copeptin in the differential diagnosis.
| CONCLUSIONS
The use of more sensitive biomarkers such as hsTNT suggests that subclinical cardiac stress in association with GCS occurs in about 25% of the patients, possibly reflecting cardiac microinjuries with potentially dangerous consequences if a critical amount of damage has accumulated with recurrent GCS. Copeptin appears to be a highly sensitive marker of GCS, but its specificity needs to be assessed in future studies. Because suPAR was not affected by GCS it might be a useful biomarker to distinguish between seizurerelated cardiac stress and cardiac ischemia.
